Biological features and clinical outcome in infant neuroblastoma: a multicenter experience in Beijing
Autor: | Rong Liu, Tian Zhi, Yan Su, Qing Sun, Xiaolun Zhang, Yao Xie, Hong Qin, Yang Xu Gao, Long Li, Zhaoxia Zhang, Dongsheng Huang, Xiaoli Ma, Wei-hong Zhao, Weiling Zhang, Huanmin Wang, Mei Jin, Shihan Zhang |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
China medicine.medical_specialty medicine.medical_treatment Disease Metastasis Neuroblastoma 03 medical and health sciences 0302 clinical medicine 030225 pediatrics Internal medicine medicine Humans 030212 general & internal medicine Child Neoplasm Staging Retrospective Studies Cause of death Chemotherapy business.industry Infant Soft tissue Retrospective cohort study Prognosis medicine.disease medicine.anatomical_structure Pediatrics Perinatology and Child Health Disease Progression Female Bone marrow business |
Zdroj: | European Journal of Pediatrics. 180:2055-2063 |
ISSN: | 1432-1076 0340-6199 |
DOI: | 10.1007/s00431-021-03989-1 |
Popis: | Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, with 37% of patients diagnosed during infancy. This study is aimed at evaluating the survival outcome in infants diagnosed with neuroblastoma. This was a retrospective cohort study including patients under the age of 12 months with neuroblastoma from four tertiary referral centers in Beijing, China (Beijing Children's Hospital, Beijing Tongren Hospital, Peking University First Hospital, and Capital Institute of Pediatrics). Two hundred and forty-seven infants with neuroblastoma were included (male = 132 and female = 115). 91.1% (n = 225) patients were classified as having low-risk or intermediate-risk disease and 8.9% (n = 22) as having high-risk disease. The most common metastatic site is distant lymph node (n=89, 36.0%), followed by liver (n=57, 23.1%), bone (n=42, 17.0%), bone marrow (n=37, 15.0%), soft tissue (n=25, 10%), and central nervous system (n=4, 1.6%). MYCN amplification was present in 9.9% of tumor samples, chromosome 1p or 11q aberration in 14%. Treatment involved surgery alone in 9.7% of patients (n=24, all with low-risk disease), surgery followed by adjuvant chemotherapy in 50.2% (n=124), neoadjuvant chemotherapy followed by surgery in 40.1% (n=97), and chemotherapy alone in 0.8% (n=2). 4.9% (n=12) patients died, and the major cause of death is disease progression. Three-year event-free and overall survival were 91.6%±2.1% and 97.4%±1.1%, respectively, in patients with low- or intermediate-risk disease, and 58.7%±11.5% and 63.6%±11.2%, respectively, in those with high-risk disease.Conclusions: Infants with neuroblastoma achieve a reasonable clinical outcome when treated with surgery with or without chemotherapy using a risk-stratified approach in China. Such information will facilitate counseling, therapeutic decision-making, and development of adapted standard-of-care guidelines for future patients in the country. What is Known: • NB is a disease of infancy; 37% of patients are diagnosed as infants. • Most children younger than 12 months of age have a good prognosis even in the presence of metastatic disease. What is New: • Infants with neuroblastoma achieve reasonable clinical outcome when treated with surgery with or without chemotherapy using a risk-stratified approach in China. • CNS metastasis in infants with neuroblastoma is very rare at diagnosis and had a worse prognosis than those without metastasis. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |